Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BMS-986249 |
Trade Name | |
Synonyms | BMS986249|BMS986249 |
Drug Descriptions |
BMS-986249 is a 2nd generation antibody that targets CTLA4, potentially resulting in T-cell activation and increased anti-tumor immune response (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B33). |
DrugClasses | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 |
CAS Registry Number | NA |
NCIT ID | C146765 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BMS-986249 | BMS-986249 | 0 | 0 |
BMS-986249 + Nivolumab | BMS-986249 Nivolumab | 0 | 1 |